Selinexor Fast-Tracked for Multiple Myeloma The FDA recently granted accelerated approval to selinexor (Xpovio) for multiple myeloma. This drug is an anti-CD38 monoclonal antibody that reversibly inhibits nuclear export of tumor-suppressor proteins, growth regulators, and mRNAs of oncogenic proteins by blocking exportin 1, leading to apoptosis of cancer cells. Read more.
Advertisement
Polatuzumab Approved for Large B-Cell Lymphoma The FDA recently granted accelerated approval to polatuzumab vedotin-piiq (Polivy), a CD79b-directed antibody-drug conjugate that delivers MMAE (an antimiotic agent) to bind with microtubules and kill the diving cells by inhibiting cell division, including apoptosis. The drug is indicated in combination with bendamustine and rituximab for adults who have relapsed or refractory diffuse large B-cell lymphoma after at least two prior therapies. Read more.
FDA Gives Gilteritinib the Go Ahead for Treating AML
The FDA approved gilteritinib based on a clinical trial comparing gilteritinib (Xospata) to salvage chemotherapy in adult patients with relapsed or refractory acute myeloid leukemia (AML). As a tyrosine kinase inhibitor, gilteritinib inhibits the signal transduction cascade of many proteins and thereby blocks phosphorylation pathways, starving the cancerous cells of energy required to proliferate. Read more.
